NEWS

June 22, 2016 | News

TARA Biosystems Appoints Robert Langer to Board of Directors

June 22, 2016. NEW YORK–(BUSINESS WIRE)–TARA Biosystems, Inc., a company developing physiologically relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, announced today that it has appointed biotechnology entrepreneur, scientist and engineer Robert S. Langer, Ph.D., to its board of directors. read more TARA Biosystems offers testing services …

show more

June 22, 2016. NEW YORK–(BUSINESS WIRE)–TARA Biosystems, Inc., a company developing physiologically relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, announced today that it has appointed biotechnology entrepreneur, scientist and engineer Robert S. Langer, Ph.D., to its board of directors.
read more
TARA Biosystems offers testing services on its human stem cell-derived cardiac tissue platform. The company’s platform, which is based on its proprietary Biowire™ technology, enables discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities. The Biowire technology is based on research from the laboratories of scientific co-founders Gordana Vunjak-Novakovic, Ph.D., the Mikati Foundation Professor of Biomedical Engineering and Medical Sciences at Columbia University, and Milica Radisic, Ph.D., P.Eng., Professor and Canada Research Chair in Functional Cardiovascular Tissue Engineering at the University of Toronto. Drs. Vunjak-Novakovic and Radisic are both world leaders in cardiac tissue engineering and former members of Dr. Langer’s lab at Massachusetts Institute of Technology (MIT).

World-Renowned Biomedical Engineer Robert Langer Appointed to Board of Directors

Dr. Langer is the David H. Koch Institute Professor at MIT. A founder of more than 30 life science companies and the most cited engineer in the world, Dr. Langer’s patents have been licensed or sublicensed to more than 300 pharmaceutical, chemical, biotechnology and medical device companies. He served as chairman of the U.S. Food and Drug Administration’s Science Board from 1999 to 2002, and is one of very few individuals elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors. Dr. Langer is the recipient of numerous awards and recognitions, including the 2015 Queen Elizabeth Prize for Engineering; the 2014 Kyoto Prize; the 2013 Wolf Prize in Chemistry; the 2012 Priestley Medal, the American Chemical Society’s highest honor; the 2011 National Medal of Technology and Innovation; the 2008 Millennium Prize; the 2006 National Medal of Science; the 2005 Albany Medical Center Prize; the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 1998 Lemelson-MIT Prize for being one of history’s most prolific inventors in medicine. He is also the only engineer to receive the Gairdner Foundation International Award. He holds 28 honorary doctorates including honorary degrees from Harvard and Yale.

“Through its cutting-edge, cardiac tissue engineering technology, TARA Biosystems has rapidly demonstrated promise to improve the efficiency of the drug development process and accelerate patients’ access to innovative therapies,” said Dr. Langer. “I look forward to working with the company through this exciting phase of growth.”

“Professor Langer brings a deep history in collaborating with our scientific co-founders, Drs. Vunjak-Novakovic and Radisic, through their early work on cardiac tissue engineering in his lab, and it is a privilege to have him join our board,” said Misti Ushio, Ph.D., CEO of TARA Biosystems. “His unique experience, from basic research to product launch, will be invaluable to TARA as we continue to validate and commercialize our unique predictive technology to test the safety and efficacy of new therapies and for the discovery of new drugs.”

show less
April 28, 2016 | News

Interview with Founder of TARA Biosystems.

April 28, 2016. biomedical engineering postdocs who trick skin cells into becoming stem cells, from which tissue engineers grow miniature versions of human organs that can safely screen new drugs and treat diseases. Think: organ on a chip. read more

show more

April 28, 2016. biomedical engineering postdocs who trick skin cells into becoming stem cells, from which tissue engineers grow miniature versions of human organs that can safely screen new drugs and treat diseases. Think: organ on a chip.
read more

show less
January 5, 2016 | News

TARA Biosystems Raises Seed Funding

January 5, 2016. NEW YORK, (Global Newswire) – TARA Biosystems, Inc., which provides physiologically-relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, raised $2.25 million in a seed financing to build commercial operations in New York City. Based on research from the laboratories of Columbia University Professor Gordana …

show more

January 5, 2016. NEW YORK, (Global Newswire) – TARA Biosystems, Inc., which provides physiologically-relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, raised $2.25 million in a seed financing to build commercial operations in New York City. Based on research from the laboratories of Columbia University Professor Gordana Vunjak-Novakovic and University of Toronto Professor Milica Radisic, both scientific co-founders of TARA Biosystems, the company aims to capitalize on the need for more predictive technology for testing the safety and efficacy of new therapies and for the discovery of new drug compounds.

Harris & Harris Group led the financing with participation from the Partnership Fund for New York City and Alexandria Venture Investments. “We are fortunate to be funded by investors committed to NYC,” said Dr. Misti Ushio, founding CEO of TARA Biosystems and Managing Director of Harris & Harris Group. “With this investment, we will build our commercial operations in NYC and are enthusiastic to be a part of its growing life science community.”

“Growing the life sciences sector in New York City has been a top priority of the Partnership Fund, with a recent focus on supporting the spin-out of life sciences companies from New York’s world-class universities,” said Maria Gotsch, President and CEO of the Partnership Fund for New York City. “It is a priority for us to create new jobs here in New York City. TARA Biosystems and its ground-breaking predictive technology will be an excellent addition to the growing life sciences ecosystem in New York.”

TARA Biosystems offers testing services on its human stem cell-derived cardiac tissue platform, which is based on its proprietary, patented Biowire™ technology. Professor Milica Radisic said, “We are actively working with our collaborators in the pharmaceutical industry to commercialize the TARA technology and fulfill the industry need for predictive human cardiac safety and efficacy information much earlier in the development cycle for new medicines.”

TARA Biosystems also enables discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities. Professor Gordana Vunjak-Novakovic added, “The TARA tissue also has the potential to generate new drug targets for the treatment of cardiac disease because of its ability to recapitulate adult heart biology.”

read more

show less

Contact

As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time.

TARA
430 East 29th Street
Suite #1015
New York, NY 10016
USA
info@tarabiosystems.com